Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders

Haematologica. 2005 Feb;90(2):261-2.

Abstract

The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Busulfan / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Female
  • Humans
  • Hydroxyurea / adverse effects
  • Hydroxyurea / pharmacology*
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / genetics*
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / metabolism
  • Male
  • Middle Aged
  • Myeloproliferative Disorders / drug therapy
  • Polycythemia Vera / drug therapy*
  • Retrospective Studies
  • Thrombocytosis / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Enzyme Inhibitors
  • Busulfan
  • Hydroxyurea